Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Carcinoma. According to GlobalData, Phase III drugs for Non-Small Cell Lung Carcinoma have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Repotrectinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Repotrectinib overview
Repotrectinib (Augtyro) acts as an anti-neoplastic agent. It is formulated as capsules for oral route of administration. Augtyro is indicated for the treatment of adult patients with locally advanced or metastatic ROS1–positive non-small cell lung cancer (NSCLC).
See Also:
Repotrectinib (TPX-0005) is under development for the treatment of NTRK-positive solid tumors, angiosarcoma, CNS tumor, thyroid cancer, non-small cell lung cancer, glioblastoma, non-small cell lung carcinoma, renal cell carcinoma, endometrial cancer, liver cancer, soft tissue sarcoma, anaplastic large cell lymphoma, melanoma, salivary gland, gallbladder, head and neck, and uterine cancer, non-Hodgkin lymphoma and pancreatic cancer. The drug candidate is administered through oral route in the form of capsule and suspension. It is a new chemical entity. The drug candidate acts by targeting ALK, ROS1/TRK, SRC/FAK kinase.
It was also under development for hepatocellular carcinoma (HCC).
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
For a complete picture of Repotrectinib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
